Monkeypox, Polio, Tuberculosis, and Hepatitis- Why Are We Experiencing Emergence of Multiple Infectious Diseases Simultaneously?

Aditi Bhargava
5 min readAug 7, 2022
Are vaccines the panacea or part of the problem? Re-emergence of several infectious diseases simultaneously.

While we are still reeling from mishandling of COVID-19 pandemic, the last few months have been filled with re-emergence of infectious diseases that were thought to be eradicated in the US and/or under control in the rest of the world. Polio has re-emerged in several parts of the US as well as around the world.

Unexplained hepatitis has afflicted many more children in the span of last 2 months globally than the last 2 years of COVID-19 pandemic; twelve children have received liver transplant in the UK. As of May 2022, more than 600 cases and at least 14 deaths have been reported globally. None of these children were infected with hepatitis A, the virus known to cause jaundice and/or hepatitis. “Experts” think that the otherwise harmless adenovirus and adeno-associated viruses (AAV) have become pathogenic, especially in young children whose immune system did not get a chance to develop in the last 2 years due to measures such masking, isolating, and essentially living in a bubble. But only about 20% of the unexplained hepatitis cases have adenovirus or AAV infections and about 26% had SARS-CoV-2 infection resulting in COVID-19 illness. While COVID-19 vaccines have been ruled out as the cause of this unexplained hepatitis, the science behind ascribing another virus as the cause is also unclear. So, what about those ~60% of the children that do not have adenovirus or SARS-CoV-2 infections? As I say, our immune systems follow the motto “use it or lose it” and extreme “sterile” measures imposed for prolonged periods in the last 2 years have essentially compromised our immune systems.

Several therapeutics including HPV vaccines and COVID-19 vaccines contain AAV vectors. These very same AAV vectors when used as vehicles for gene therapy have resulted in several deaths in clinical trials, leading to prompt termination of those trials. The FDA requires a minimum of 5-year follow-up for treatments that use AAV vectors, yet this is not true for COVID-19 vaccines that contain AAV vectors. The rationale for not monitoring people injected with AAV-containing COVID-19 vaccines for safety and adverse events beyond 2 months does not exist, is irresponsible, and defies science and ethics.

Aditi Bhargava

Dr. Aditi Bhargava is a molecular neuroendocrinologist with research focus on sex differences in stress biology and immunology.